Multicenter Expanded Access Protocol of Allogeneic Epstein-Barr Virus Cytotoxic T Lymphocytes (EBV-CTLs) for Patients with EBV-Associated Lymphomas and Lymphoproliferative Disorders in Immunocompromised Patients for Whom There are No Other Comparable Options
This study is evaluating a treatment for lymphomas and lymphoproliferative disorders caused by the Epstein-Barr Virus (EBV) in patients with defined defects in their immune systems who have no other treatment options. The treatment consists of white blood cells called cytotoxic T lymphocytes (CTLs) that are donated by a healthy person, grown in a laboratory to educate them to recognize and destroy EBV-infected cells, and then given by intravenous infusion (through a vein) to a patient whose EBV disorder or lymphoma matches or partially matches the EBV-CTLs.
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have an EBV lymphoma or lymphoproliferative disorder, a defect in their immune system, and no other treatment options.
- Patients must have matched or partially matched EBV-CTLs available as treatment.
- This study is open to children and adults.
For more information about this study and to inquire about eligibility, please contact Dr. Susan Prockop at 212-639-6715.